Leap Therapeutics Inc (LPTX) Shares Sold by Sphera Funds Management LTD.

Sphera Funds Management LTD. lessened its stake in shares of Leap Therapeutics Inc (NASDAQ:LPTX) by 33.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 332,525 shares of the company’s stock after selling 166,612 shares during the quarter. Sphera Funds Management LTD. owned about 2.26% of Leap Therapeutics worth $2,590,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Millennium Management LLC bought a new position in shares of Leap Therapeutics during the 1st quarter worth about $105,000. JPMorgan Chase & Co. bought a new position in shares of Leap Therapeutics during the 3rd quarter worth about $111,000. DRW Securities LLC bought a new position in shares of Leap Therapeutics during the 2nd quarter worth about $347,000. Point72 Asset Management L.P. boosted its position in shares of Leap Therapeutics by 178.0% during the 2nd quarter. Point72 Asset Management L.P. now owns 75,888 shares of the company’s stock worth $683,000 after purchasing an additional 48,588 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Leap Therapeutics by 24.7% during the 2nd quarter. Renaissance Technologies LLC now owns 112,467 shares of the company’s stock worth $1,012,000 after purchasing an additional 22,247 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors.

LPTX has been the topic of a number of research analyst reports. HC Wainwright set a $13.00 price objective on shares of Leap Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, November 13th. Zacks Investment Research raised shares of Leap Therapeutics from a “hold” rating to a “buy” rating and set a $8.25 price target on the stock in a research report on Saturday, October 6th. Finally, ValuEngine raised shares of Leap Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 30th.

Shares of NASDAQ LPTX opened at $3.17 on Friday. Leap Therapeutics Inc has a fifty-two week low of $3.13 and a fifty-two week high of $10.25.

Leap Therapeutics (NASDAQ:LPTX) last announced its quarterly earnings results on Thursday, November 15th. The company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.02). As a group, analysts forecast that Leap Therapeutics Inc will post -2.37 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This report was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.thelincolnianonline.com/2018/12/08/leap-therapeutics-inc-lptx-shares-sold-by-sphera-funds-management-ltd.html.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.

Recommended Story: Moving Average – How it Helps Investors in Stock Selection

Institutional Ownership by Quarter for Leap Therapeutics (NASDAQ:LPTX)

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply